This activity is supported by an unrestricted educational grant from Astellas Pharma US, Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, Inc., Pfizer

Navigating the Landscape of Molecular Testing and Treatments With Targeted Therapies for Patients With Non-Small Cell Lung Cancer

Sukhmani K. Padda, MD
Stanford Cancer Institute

R. Donald Harvey, PharmD, FCCP, BCOP
Winship Cancer Institute of Emory University

Keeping current with emerging targeted therapies for NSCLC can be daunting yet exciting.  There are multiple options for first, second and even third line treatment, which can effectively delay progression or improve overall survival.  This activity provides the AP with a valuable overview and update on NSCLC targeted therapies, molecular testing and recommendations for optimizing patient outcomes with newer emerging treatment options.


Download Podcast


Download Transcript


Download Slides


Download Slides & Transcripts


These CME/CE/CPE accredited activities are jointly provided by

JADPRO CE Logo Harborside Press Logo APSHO Logo Annenberg Logo
Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.